Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing

Professional paper - Letter to the editor

• Author: Vladimir Trkulja
• Author's institution: University of Zagreb; School of Medicine; (Department of Pharmacology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Basic Medical Sciences; Pharmacology
• Keywords (english): Adenosine Monophosphate / administration & dosage; Adenosine Monophosphate / analogs & derivatives*; Airway Management / methods; Alanine / administration & dosage; Alanine / analogs & derivatives*; Antiviral Agents / administration & dosage; COVID-19* / diagnosis; COVID-19* / drug therapy; COVID-19* / mortality; COVID-19* / physiopathology; Disease Progression; Humans; Hypoxia / etiology; Hypoxia / therapy; Mortality; Patient Selection; Pneumonia, Viral* / etiology; Pneumonia, Viral* / physiopathology; Pneumonia, Viral* / therapy; Randomized Controlled Trials as Topic; Respiratory Insufficiency* / blood; Respiratory Insufficiency* / etiology; Respiratory Insufficiency* / therapy; SARS-CoV-2; Time-to-Treatment*; Treatment Outcome
• Language: english
• Publication type: Professional paper - Letter to the editor
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: European Journal of Clinical Pharmacology
• Numbering: vol. 77, no. 6, pp. 935-937
• p-ISSN: 0031-6970
• e-ISSN: 1432-1041
• DOI: https://doi.org/10.1007/s00228-020-03085-7
• URN:NBN: urn:nbn:hr:105:524286
• Publication: 2021-01-06
• Document URL: https://link.springer.com/10.1007/s00228-020-03085-7
• Type of resource: Text
• Access conditions: Open access
• Created on: 2021-07-12 08:26:34